关于局部复发的直肠癌的荷兰国家指导方针
Floor Piqeur1, Davy M J Creemers2, Evi Banken3
1Department of Radiation Oncology, Catharina Hospital, Michelangelolaan 2 5623EJ, Eindhoven, the Netherlands; Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121 1066 CX, Amsterdam, the Netherlands; Department of Radiation Oncology, Leiden University Medical Centre, Albinusdreef 2 2333ZA, Leiden, the Netherlands.
Cancer treatment reviews
|May 2, 2024
概括
局部直肠癌复发 (LRRC) 影响6-12%的患者,尽管改善了初级治疗. 本指南为LRRC提供了全面的管理策略,解决复杂的病例并指导临床决策.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 初级直肠癌治疗的改进降低了局部复发率.
- 然而,6-12%的患者仍然会出现局部直肠癌复发 (LRRC).
- 管理LRRC是复杂的,因为异构的陈述和有限的数据.
研究的目的:
- 为LRRC的临床管理制定全面的国家指导方针.
- 向临床医生指导从诊断到手术治疗的整个途径.
- 解决LRRC中标准化,多学科护理的需求.
主要方法:
- 进行了全面的叙事文献综述.
- 该审查为制定荷兰国家LRRC管理指南提供了信息.
- 该指南重点关注从诊断到手术的整个临床途径.
主要成果:
- 现有的指南为LRRC诊断和治疗提供了有限的指导.
- 具有专业专业知识的多学科方法对于有效的LRRC管理至关重要.
- 开发的指南旨在标准化临床医生的决策.
结论:
- 尽管发病率下降,但LRRC仍然是一个重大的临床挑战.
- 基于证据的全面指导方针对于最佳的LRRC患者护理至关重要.
- 荷兰国家准则为通过多学科方法管理LRRC提供了一个框架.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


